Osimertinib
astrazeneca
['breast', 'increase,(-increased)']
although increase in recurrences after stopping is consistent w earlier trials, the phenomenal control while on osi (much longer than stage 4 pfs) suggests to me pts (at least stg3) shouldn't stop after 3 years. adjuvant hrt in breast cancer 10yrs&gt;5&gt;3, should be tested. #esmo22 
Professor and thoracic oncologist, Vice Chair Clinical Research @ClevelandClinic TCI, @ASCO #EdBook Editor in Chief, Dad, Steelers fan. All opinions mine. #LCSM